Effect of folate treatment on the risk of adenomas, by MTHFR genotype
| Genotype | Any adenoma | Advanced adenoma* | ||||
|---|---|---|---|---|---|---|
| Ns† | Folate/Placebo RR‡ (95% CI) | Ns† | Folate/Placebo RR (95% CI) | |||
| 677C>T (n) Folate/Placebo† | Folate /Placebo† | Folate/Placebo | ||||
| CC (204/201) | 96/86 | 1.09 (0.87-1.36) | 21/22 | 0.96 (0.54-1.68) | ||
| CT (203/197) | 93/84 | 1.06 (0.85-1.33) | 22/15 | 1.48 (0.78-2.79) | ||
| TT (43/50) | 16/20 | 0.93 (0.57-1.53) | 4/4 | 1.30 (0.34–4.96) | ||
| 1298A>C (n) | ||||||
| AA (218/226) | 91/91 | 1.01 (0.81-1.26) | 22/21 | 1.11 (0.62-1.98) | ||
| AC (189/190) | 94/84 | 1.11 (0.89-1.39) | 21/17 | 1.22 (0.66-2.27) | ||
| CC (44/33) | 20/16 | 1.02 (0.62-1.68) | 6/3 | 1.40 (0.36-5.38) | ||
| MTHFR 677/1298 Genotype† | ||||||
| CC/AA (69/68) | 27/28 | 0.90 (0.60-1.35) | 4/10 | 0.39 (0.13-1.19) | ||
| CC/AC (92/100) | 49/42 | 1.25 (0.92-1.72) | 13/9 | 1.41 (0.62-3.22) | ||
| CC/CC (43/33) | 20/16 | 1.04 (0.63-1.72) | 6/3 | 1.44 (0.37-5.54) | ||
| CT/AA (106/108) | 48/43 | 1.12 (0.82-1.53) | 14/7 | 2.05 (0.85-4.95) | ||
| CT/AC (97/89) | 45/41 | 0.99 (0.72-1.37) | 8/8 | 0.99 (0.38-2.55) | ||
| TT/CC (43/50) | 16/20 | 0.93 (0.56-1.53) | 4/4 | 1.30 (0.34-4.95) | ||
↵* Advanced adenoma defined as tubulovillous or villous adenoma, large adenoma (≥1 cm), carcinoma in situ, or invasive cancer.
↵† Number of subjects in folate/placebo treatment groups.
↵‡ RR, risk ratio for effect of 1 mg/day folate supplement versus placebo on adenoma recurrence risk; RRs were adjusted for age, sex, clinical center, and aspirin treatment assignment.